NYMXF — Nymox Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- $5.23m
- $5.15m
Annual income statement for Nymox Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.005 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.001 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.7 | 12.5 | 6.65 | 8.79 | 4.28 |
| Operating Profit | -11.7 | -12.5 | -6.65 | -8.79 | -4.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.7 | -12.5 | -6.58 | -8.84 | -4.49 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.7 | -12.5 | -6.58 | -8.84 | -4.49 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.7 | -12.5 | -6.58 | -8.84 | -4.49 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.7 | -12.5 | -6.58 | -8.84 | -4.49 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.159 | -0.153 | -0.074 | -0.092 | -0.048 |